High-Density POEGMA Conjugates for Reduced Immune Recognition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

PEGylated biologically active agents, such as uricase, induce significant immune responses and infusion reactions due to high immunogenicity and PEG-specific antibodies, limiting their clinical utility.

Innovation Solution

Conjugating a biologically active agent with high-density POEGMA molecules, each with a poly(methyl methacrylate) backbone and 2 to 9 ethylene glycol monomers, to reduce immunogenicity and improve pharmacokinetics.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PEG molecules are conjugated to biologically active agents to improve solubility and stability, then the pharmacokinetic profile is improved, but immunogenicity increases and immune responses are induced

Engineering Contradiction:

Improvepharmacokinetic profileVSAvoidimmunogenicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical structure parameter of the polymer from PEG to POEGMA, which has a poly(methyl methacrylate) backbone with ethylene glycol side chains. This structural parameter change maintains the beneficial pharmacokinetic properties while eliminating the immunogenicity issue that plagued PEGylated products

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses POEGMA, which is a composite polymer structure combining a poly(methyl methacrylate) backbone with ethylene glycol side chains. This composite structure integrates the hydrophilic properties needed for good solubility and pharmacokinetics while the unique architecture reduces immune recognition compared to conventional PEG

Inventive Principle:

Principle #40Composite materials

2Duration of action of moving object

If high density PEG conjugates are used to extend drug half-life, then duration of action is improved, but immune system activation and infusion reactions increase

Engineering Contradiction:

Improvedrug half-lifeVSAvoidimmune system activation

Core Design Contradiction:

Duration of action of moving objectVSObject-generated harmful factors

Solution Approach 1:

The patent changes the polymer density parameter by conjugating high densities of POEGMA molecules (about 5 to about 130 molecules per biologically active agent) to extend half-life, while the POEGMA structure itself prevents immune activation even at these high densities, unlike PEG which caused dose-dependent immune reactions

Inventive Principle:

Principle #35Parameter changes

3Productivity

If PEGylated uricase is administered to treat chronic refractory gout, then therapeutic efficacy is improved, but anti-drug antibody formation accelerates drug clearance

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoiddrug clearance rate

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent changes the polymer identity parameter from PEG to POEGMA in the conjugate structure. This change maintains the extended circulation time and therapeutic efficacy needed for treating gout, while preventing the formation of anti-drug antibodies that would otherwise accelerate clearance and limit long-term treatment utility

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250332269A1Non-immunogenic, high density poegma conjugates

Publication Date: 2025.10.30 DUKE UNIV

AI summary

Disclosed are high density POEGMA-biologically active agent conjugates that have advantageous pharmacokinetics, while also having a reduced or eliminated host-immune response. An example conjugate includes a biologically active agent and a plurality of POEGMA molecules conjugated to the biologically active agent, each POEGMA molecule having a poly(methyl methacry late) backbone and a plurality of side chains covalently attached to the backbone, each side chain including 2 to 9 monomers of ethylene glycol repeated in tandem. Also disclosed are methods of reducing the immunogenicity of a polymer-biologically active agent conjugate.